SEC enforcement narrows focus
The Securities and Exchange Commission is recalibrating enforcement toward core investor‑protection priorities such as fraud, market manipulation and issuer disclosures, even as total actions fall compared with prior years. Law‑firm analyses say the tilt means fewer overall cases but continued risk for companies that misstate strategy or fail to disclose material issues. (reuters.com)
The Securities and Exchange Commission is bringing fewer cases, but it is concentrating more of them on fraud, market manipulation and false corporate disclosures. (sec.gov) On April 7, the agency said it filed 456 enforcement actions in fiscal 2025, including 303 standalone cases, down 22% and 30% from fiscal 2024. It also said 1,095 investigations were closed without charges, a figure it had not previously published in its annual results. (sec.gov; cooley.com) The headline dollar figure was $17.9 billion in monetary relief, but $14.9 billion came from the long-running Robert Allen Stanford Ponzi scheme case first filed in 2009. Excluding that case and amounts satisfied in parallel proceedings, outside lawyers said the total was closer to $2.7 billion. (sec.gov; cooley.com; davispolk.com) The shift follows a change in leadership after Commissioner Mark Uyeda became acting chair on January 21, 2025, and Paul Atkins took over as chair on April 21, 2025. Judge Margaret Ryan became enforcement director on September 2, 2025, and senior officials have since described a “back to basics” approach centered on investor harm and market integrity. (mcdermottlaw.com; alston.com) In its results release, the commission said earlier resources had been spent chasing “media headlines” and case counts, and it singled out off-channel communications, crypto registration and “dealer” definition cases as examples of matters it views as less tied to direct investor harm. Davis Polk said that language marked a break from the prior commission’s emphasis on volume and novel legal theories. (sec.gov; davispolk.com) That does not mean disclosure cases are disappearing. The commission’s own examples included issuer disclosure violations, and Cooley pointed to a settled case against a public biopharmaceutical company that allegedly hid a severe Food and Drug Administration critique while making optimistic statements in initial public offering documents; the company agreed to pay a $2.5 million penalty. (sec.gov; cooley.com) Law firms reviewing the new posture say the practical change is selectivity, not leniency. McDermott wrote in January that the agency is expected to pursue fewer matters, but to keep targeting “material misrepresentations” and significant investor harm, especially by executives and directors. (mcdermottlaw.com) The commission is also putting more weight on charging individuals. Cooley said nearly 90% of standalone actions filed after the January 20, 2025 presidential inauguration included charges against individuals, reflecting the agency’s stated push for individual accountability. (cooley.com) For public companies, the message in the 2026 cases is narrower than the raw totals suggest: technical compliance issues may draw less attention, but statements about strategy, financial condition, product prospects and other material facts still sit squarely in the enforcement crosshairs. (alston.com; sec.gov)